Oculogenex (NSF-2208096) develops gene therapy to treat retinal disorders and improve vision for patients. The company is collaborating with scientists aboard the International Space Station (ISS) to conduct a new study on macular degeneration. SpaceX sent 40 mice into space to evaluate how gene therapy can help prevent vision loss caused by space travel. Article via ABC7